Latest news with #Rockville
Washington Post
a day ago
- General
- Washington Post
The AC broke at an animal shelter. People lined up out the door to foster pets.
Katie Boord was scrolling through Facebook on Monday evening, enjoying the aroma of the chicken macaroni and cheese her husband was cooking, when a post appeared on her phone that made her panic. An animal shelter in Derwood, Maryland, wrote: 'URGENT: Short-Term Fosters Needed for Shelter Animals.' The shelter's air conditioning was broken, the shelter said, putting hundreds of animals at risk of heat exhaustion. 'I have to do something,' Boord recalled telling her husband, Sean Clayton. 'Go ahead,' Boord recalled Clayton replying. 'I'll keep dinner warm.' Boord rushed to the Montgomery County Animal Services and Adoption Center from her Rockville, Maryland, home, joining dozens of others who came on short notice to foster animals after seeing the shelter's message. Boord left with three cats named Sponge Bob, Sandy Cheeks and Gary. The trio was among the roughly 70 animals who were fostered from the shelter this week as Montgomery County employees worked to fix the air conditioning amid a heat dome — a heat-trapping lid of strong high pressure — that brought extreme humidity and temperatures around 100 degrees to the D.C. area. Maria Anselmo, the shelter's community relations manager, said employees didn't expect such a large outpouring of help. 'Half of us probably cried at some point over the past couple days [from joy],' Anselmo told The Washington Post. When employees reported to the shelter Monday morning, Anselmo said, the air conditioning wasn't working. They called the county's Department of General Services, which found a broken air-conditioning motor that could be fixed in about 24 hours. Shelter employees set up fans and cooling mats throughout their building. They froze Kong dog toys and limited their animals' time outdoors. Employees emailed former foster volunteers for help. But they realized that wasn't enough people, Anselmo said, so they posted on social media in the late afternoon Monday. 'We're urgently seeking short-term foster homes for dogs and cats,' the shelter wrote, adding: 'Even a weekend foster makes a difference. You'll give a shelter pet a much-needed break from the heat and help us free up space during this critical time.' As hundreds of Montgomery County residents and Maryland animal lovers shared the post, people began showing up at the shelter within minutes. The shelter's phones wouldn't stop ringing. Soon, a line formed outside the front door. While the shelter usually asks foster volunteers to complete an application and schedule an appointment to meet employees and animals, the staff simply asked Monday for each volunteer's ID, address, phone number and email. 'We had so many people just show up who were ready to jump in and help that we weren't going to turn those people away,' said Anselmo, 37. After Boord arrived that evening, she said, she waited about an hour for employees to give her three cats who had come to the shelter from the same home — Sponge Bob and Sandy Cheeks, both of whom are around 2 years old, and Gary, about 10 months old. Boord and Clayton already had an 8-year-old cat, Fillion, at home. While Boord was at the shelter, Clayton set up their guest room for the foster cats with cat food, a litter box, water bowls, toys and a cat bed. While the cats were initially scared, they began playing with a spring toy the next day, and Gary, who initially wouldn't come out from his light blue blanket, cuddled with Boord, 34, a special-education teacher. At the shelter, employees worked until around 10 p.m. Monday. One of the many calls they received came from Debbie Lauer, who saw the shelter lost air conditioning while watching the evening news as she ate a chicken skewers dinner. Lauer had wanted to foster a dog since she retired last month from the National Security Agency. On Tuesday, Lauer's 67th birthday, she drove about 16 miles south from her Mount Airy, Maryland, home to pick up Princess Daisy, a roughly 1-year-old terrier mix with a white and brindle coat. 'It's just feeling like you're doing something good,' Lauer said. 'I'm glad I did it. I will continue to do it.' The county fixed the shelter's air conditioning Tuesday, and the shelter emailed fosters that afternoon to say they could return the animals. But Ilya Albert, who began fostering Teton, an 11-month-old brown cat, on Monday, didn't want to say goodbye. Albert and his wife, Jessica DePrest, had considered adopting a cat since their longtime cat, Jones, died last month. At their Rockville home, Teton cuddled with DePrest, jumped atop their cat trees and purred when they picked him up. When Albert's 6-month-old daughter, June, pulled Teton's whiskers, Teton seemed unbothered. 'He felt like he was already a family member,' said Albert, 37, who works in marketing. Albert told the shelter Wednesday he and DePrest wanted to adopt Teton. They renamed him Jake — based on the cat from the 1978 movie 'The Cat From Outer Space.' Boord returned her cats Thursday, and Lauer is seeking an adopter for Princess Daisy. About 40 dogs, 20 cats and 10 small animals — rabbits, guinea pigs, ferrets and a chinchilla — were fostered this week, Anselmo said. The shelter thanked the volunteers in a statement Wednesday. 'This response has left us speechless,' the shelter wrote. 'How do we even begin to express our gratitude for each and every one of you?' To Anselmo, that starts by responding to every email and social media message the shelter received this week — a task she expects to take a few days. 'In the meantime: All animals are safe, cared for, and cool… thanks to YOU,' the shelter wrote.
Yahoo
6 days ago
- Sport
- Yahoo
Nationals' James Wood breaks 50 RBIs with 2-run blast vs. Rockies
The post Nationals' James Wood breaks 50 RBIs with 2-run blast vs. Rockies appeared first on ClutchPoints. Washington Nationals left fielder James Wood broke the 50 RBI mark with a clutch 2-run blast against the Colorado Rockies. The Nationals were riding an eight-game losing streak heading into this clash and falling significantly behind in the playoff hunt. The franchise has been rebuilding since its World Series title in 2019, going through several trying seasons. Advertisement While it's been a long road back to relevance, this roster now has a few encouraging young players. The headline star is Wood, a 22-year-old whom the Nationals acquired via the Juan Soto deal in 2022. And there's a chance that Washington's left fielder goes on to have an even better career than Soto. Wood hit his 18th home run of the season against the Rockies on Monday, while recording his 51st RBI. With more than half of the season to go, the 6-foot-7, 234-pound lefty will have plenty of highlights like the one below. A former second-round pick out of Rockville, Maryland, Wood was ranked as the top prospect in the Nationals' farm system in 2023. From there, it's been a relatively seamless transition to big-league play. The young left fielder showed a lot of promise in his 79 games of action last season. And this year, Wood has elevated his game to an All-MLB level, leading Washington in batting average, home runs, RBIs, on-base percentage, and hits. Advertisement While the team's best hitter is still developing on defense, he is a tremendous athlete with an above-average arm. Wood, therefore, is this team's future, and it's very encouraging seeing him continue this positive momentum in the nation's capital. Overall, it won't be easy for the Nationals to make it to the playoffs with the way their division and league are shaping up over these next few years. But this franchise is slowly but surely working its way back to relevance and has the face to build around for the foreseeable future. Related: Nationals' Daylen Lile hits 1st MLB home run vs. Rockies Related: Davey Martinez passionately defends coaches amid Nationals' brutal slump
Washington Post
20-06-2025
- Automotive
- Washington Post
Government drops cases against ‘predatory' financial firms
One after another, the debtors were called to stand before the judge. First came Adrian Vega, a painter, and his wife, Natalie, a cleaner. Moments later, Andrew Vanderhoof, a mechanic. In rapid succession, three more names were called. Each was being sued by Credit Acceptance Corporation, one of the nation's largest subprime auto lenders, for thousands of dollars. This scene played out last month in Rockville, Illinois, but it has been repeated in courtrooms across the country. Every month, Credit Acceptance files hundreds of lawsuits against borrowers.
Medscape
19-06-2025
- Health
- Medscape
One Psilocybin Dose Eases Cancer Depression Over Long Term
A single dose of psilocybin combined with psychological support can provide lasting relief from depression and anxiety in patients with cancer. In a phase 2 clinical trial, more than half of patients reported sustained reductions in depression, and nearly half reported significant reductions in anxiety 2 years after treatment. Psilocybin is a 'potentially paradigm-shifting alternative to traditional antidepressants,' wrote the investigators, led by Manish Agrawal, MD, Sunstone Therapies, Rockville, Maryland. Sandeep Nayak, MD, medical director, Johns Hopkins Center for Psychedelic and Consciousness Research, Baltimore, who wasn't involved in the study, said that the antidepressant effects of psilocybin in patients with cancer are 'consistent' with those found in larger studies of people with depression. 'If psilocybin works for major depression in general, it's likely to work for major depression in people with cancer, even though there are, of course, unique aspects of psychological suffering with cancer,' Nayak told Medscape Medical News . He cautioned, however, that more study is needed. 'Ultimately, this data is encouraging but not a game changer,' said Nayak. 'We do need bigger studies, which are coming.' Limited Success Treating Cancer Depression Depression remains common in patients with cancer, and the typical treatment approaches — antidepressants and psychotherapy — have demonstrated limited success. Agrawal and colleagues explored the safety, feasibility, and efficacy of psilocybin-assisted group therapy in 30 patients (mean age, 58 years; 70% women; 80% White individuals) with major depressive disorder and curable or noncurable cancer. Participants received one-on-one and group therapy sessions before, during, and after receiving a single 25-mg psilocybin dose. No patients were taking an antidepressant or antipsychotic medications or using medical cannabis. Earlier results from this trial showed that, at 8 weeks posttreatment, 25 of 30 patients (80%) had a lasting response to psilocybin, with half demonstrating full remission of depressive symptoms by week 1, which lasted for at least 8 weeks. The latest findings explore depression after 2 years in the 28 patients available for follow-up (two patients died). The new 2-year data, published June 16 in the journal Cancer , highlight the durability of these effects. At 2 years, 15 patients (54%) demonstrated ongoing benefit, with a significant 15-point reduction in Montgomery-Åsberg Depression Rating Scale scores, 14 of which had full remission of depressive symptoms. Psilocybin also helped relieve anxiety. At 2 months, 22 patients (79%) had a significant 17-point reduction from baseline in Hamilton Anxiety Rating Scale, with 13 (46%) having a sustained reduction in anxiety at 2 years (average, 13.9-point reduction from baseline). 'Impressive' Data With Caveats Nayak said the fact that 50% of patients with cancer were in remission from their depression at 2 years is 'impressive and consistent with a long-lasting antidepressant effect of psilocybin.' 'However, the study had no control group, which is a limitation in that we can't tell how much of the benefit was from the intervention vs other causes (placebo effect, depression improving on its own, social support following the trial),' he noted. 'If psilocybin receives approval for major depressive disorders, studies like this will I think spur clinical work with psilocybin and cancer,' Nayak said. So why does psilocybin relieve depression? 'There are a lot of theories,' F. Perry Wilson, MD, Yale School of Medicine, New Haven, Connecticut, and Medscape's Impact Factor commentator, said in a recent post. Wilson noted that some researchers are using a new term — psychoplastogens — to describe drugs like psilocybin. 'The science suggests that one-time use of these agents can allow for a sudden increase in neural plasticity, allowing new neuronal connections to form where they wouldn't in other conditions, and for older connections to break down and restructure,' Wilson explained. 'If our brains are etched with the stories of our lives, if our behaviors deepen and reinforce those psychological ruts, psychoplastogens like psilocybin may loosen the soil, so to speak.' This also suggests that concomitant psychotherapy could be a critical component of psilocybin treatment for depression, he added. 'Perhaps the psilocybin shakes loose some maladaptive pathways, but putting them together in a healthy way still takes work.' Wilson said it wouldn't surprise him if this is the case, 'and it's a good reminder to those of you reading this that these drugs are not a panacea for mental health.'
Yahoo
16-06-2025
- Business
- Yahoo
Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio
Proposed acquisition expected to accelerate mid- to long-term revenue and cash flow growth and further diversify revenue base. Strengthens Supernus' leading presence in neuropsychiatric conditions with an innovative commercial product, ZURZUVAE® (zuranolone), and a novel CNS discovery platform. Expected to be significantly accretive in 2026 with potential cost synergies of up to $200 million on an annual basis. Upfront cash payment of $8.50 per share, plus one non-tradable contingent value right (CVR) payable upon achieving certain specific milestones collectively worth up to $3.50 per share in cash, for an aggregate of up to approximately $795 million or $12.00 per share. Supernus to host conference call and webcast today at 8:30 a.m. ET. ROCKVILLE, Md. and CAMBRIDGE, Mass., June 16, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) and Sage Therapeutics, Inc. (Nasdaq: SAGE), today announced a definitive agreement for Supernus to acquire Sage through a tender offer for $8.50 per share in cash (or an aggregate of approximately $561 million), payable at closing, plus one non-tradable contingent value right (CVR) collectively worth up to $3.50 per share in cash (or an aggregate of approximately $234 million), for total consideration of $12.00 per share in cash (or an aggregate of up to approximately $795 million). The CVR is payable upon achieving certain net sales and commercial milestones. The transaction is expected to close in the third quarter of 2025. The transaction will provide Supernus with an innovative marketed product: ZURZUVAE® (zuranolone) capsules CIV, the first and only U.S. Food and Drug Administration (FDA)-approved oral medicine indicated for the treatment of adults with postpartum depression. Through a collaboration agreement with Biogen, Inc., Supernus will report collaboration revenue that is 50% of total net revenue Biogen records for ZURZUVAE in the U.S. 'This acquisition represents a major step in bolstering our future growth. It augments our growth profile by adding a significant fourth growth product to our portfolio and further diversifies our sources of future growth. ZURZUVAE aligns with our focus of acquiring novel value-enhancing and clinically-differentiated medicines to treat CNS conditions,' said Jack Khattar, President and CEO of Supernus Pharmaceuticals. 'We have a proven track record of strong commercial execution, and we look forward to building on ZURZUVAE's U.S. growth momentum and collaboration with Biogen, so that more women with postpartum depression can benefit from this novel treatment.' 'Since our founding, Sage Therapeutics has been committed to pioneering new solutions in brain health, one of the most complex and underserved areas of medicine,' said Barry Greene, Chief Executive Officer, Sage Therapeutics. 'We are proud of what we've accomplished, including successfully developing and commercializing ZURZUVAE, the first and only oral treatment for women with postpartum depression. This transaction follows a comprehensive strategic review by our Board of Directors, and I am confident this deal maximizes value for shareholders. I want to express my deepest gratitude to the Sage team for their unwavering commitment to brain health and improving the lives of patients. We look forward to our next chapter with Supernus.' Strategic and Financial Benefits Strengthens psychiatry portfolio with ZURZUVAE® (zuranolone) capsules CIV, the first and only FDA-approved oral medicine indicated for the treatment of postpartum depression in adults. Diversifies and increases revenue base and cash flow. Collaboration revenue from net sales of ZURZUVAE (representing 50% of the net revenue recorded by Biogen) was $36.1 million and $13.8 million for the full year 2024 and for the first quarter of 2025, respectively. Combined with its three other growth products (Qelbree®, ONAPGOTM, and GOCOVRI®), Supernus believes it is poised for significant future growth. Augments Supernus central nervous system (CNS) discovery platforms and expertise. Strong fit with existing Supernus infrastructure is expected to result in cost synergies of up to $200 million on an annual basis. The acquisition is expected to be significantly accretive in 2026. Terms and Financing Under the terms of the agreement, Supernus will commence a tender offer to acquire all outstanding shares of Sage Therapeutics, Inc. for a purchase price of $8.50 per share in cash (or an aggregate of approximately $561 million) payable at closing plus one non-tradable CVR. All cash consideration will be funded through existing balance sheet cash. The CVR entitles Sage stockholders to receive up to an additional $3.50 per share payable upon ZURZUVAE achieving certain sales and commercial milestones within certain specified periods (subject to the terms and conditions contained in a Contingent Value Rights Agreement detailing the terms of the CVR). These milestones include (1) $1.00 per share payable if in any calendar year between closing and end of 2027, annual net sales of ZURZUVAE allocable to Supernus reach $250 million or more in the U.S., (2) $1.00 per share payable if in any calendar year between closing and end of 2028, annual net sales of ZURZUVAE allocable to Supernus reach $300 million or more in the U.S., (3) $1.00 per share payable if in any calendar year between closing and end of 2030, annual net sales of ZURZUVAE allocable to Supernus reach $375 million or more in the U.S., and (4) $0.50 per share at first commercial sale in Japan to a third-party customer after regulatory approval for ZURZUVAE for the treatment of major depressive disorder (MDD) in Japan by June 30, 2026. Approvals and Timing of Close The transaction, which has been approved by the boards of directors of both companies, is expected to close in the third quarter of 2025, subject to customary closing conditions, including receipt of required regulatory approvals and the tender of a majority of the outstanding shares of Sage's common stock. Following the successful closing of the tender offer, Supernus will acquire any shares of Sage that are not tendered in the tender offer through a second-step merger at the same consideration as paid in the tender offer. Full Year Financial Guidance Supernus will provide revised full year 2025 financial guidance after the closing of the transaction, which is expected in the third quarter of 2025. Advisors Moelis & Company LLC is acting as the exclusive financial advisor to Supernus. Goldman Sachs & Co. LLC is acting as the exclusive financial advisor to Sage. Saul Ewing LLP is serving as legal counsel to Supernus. Kirkland & Ellis LLP is serving as legal counsel to Sage. Conference Call and Webcast Information A conference call and a live webcast will be hosted today, June 16, 2025, at 8:30 a.m. ET, to discuss the transaction. A live webcast will be available in the Events & Presentations section of the Supernus Investor Relations website Participants may also pre-register any time before the call here. Once registration is completed, participants will be provided a dial-in number with a personalized conference code to access the call. Please dial in 15 minutes prior to the start time. Following the live call, a replay will be available on the Supernus Investor Relations website The webcast will be available on the Supernus website for 60 days following the live call. About Supernus Pharmaceuticals, Inc. Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Our diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, epilepsy, migraine, cervical dystonia, and chronic sialorrhea. We are developing a broad range of novel CNS product candidates including new potential treatments for epilepsy, depression, and other CNS disorders. For more information, please visit About Sage Therapeutics Sage Therapeutics (Nasdaq: SAGE) is a biopharmaceutical company committed to our mission of pioneering solutions to deliver life-changing brain health medicines, so every person can thrive. Sage developed the only two FDA-approved treatments indicated for postpartum depression and is advancing a pipeline to target unmet needs in brain health. Sage was founded in 2010 and is headquartered in Cambridge, Mass. Find out more at or engage with us on Facebook, LinkedIn, Instagram, and X. For more information about ZURZUVAE, please visit Additional Information About the Tender Offer and Where to Find It The tender offer for the outstanding common stock of Sage Therapeutics, Inc. ('Sage') has not been commenced. This filing does not constitute a recommendation, an offer to purchase or a solicitation of an offer to sell Sage securities. At the time the tender offer is commenced, Supernus Pharmaceuticals, Inc. ('Supernus') will file a Tender Offer Statement on Schedule TO (including an Offer to Purchase) with the Securities and Exchange Commission (the 'SEC') and thereafter, Sage will file a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC, in each case, with respect to the tender offer. The solicitation and offer by Supernus to purchase shares of Sage common stock will only be made pursuant to such Offer to Purchase and related materials. Once filed, investors and security holders are urged to read these materials (including the Offer to Purchase, a related Letter of Transmittal and certain other tender offer documents, as each may be amended or supplemented from time to time) carefully since they will contain important information that Sage investors and security holders should consider before making any decision regarding tendering their common stock, including the terms and conditions of the tender offer. The Tender Offer Statement, Offer to Purchase, Solicitation/Recommendation Statement and related materials will be filed with the SEC, and Sage investors and security holders may obtain a free copy of these materials (when available) and other documents filed by Supernus, Purchaser and Sage with the SEC at the website maintained by the SEC at In addition, the Tender Offer Statement and other documents that Supernus and Purchaser file with the SEC will be made available to all investors and security holders of Sage free of charge from the information agent for the tender offer. Investors may also obtain, at no charge, the documents filed with or furnished to the SEC by (i) Supernus under the 'Investor Relations' section of Supernus's website at and (ii) Sage under the 'Investors & Media' section of Sage's website at Supernus Forward-Looking Statements This press release includes forward-looking statements. These statements do not convey historical information but relate to predicted or potential future events that are based upon management's current expectations. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. In addition to the factors mentioned in this press release, such risks and uncertainties include, but are not limited to, the risk that the proposed acquisition of Sage by Supernus may not be completed; the possibility that competing offers or acquisition proposals for Sage will be made; the delay or failure of the tender offer conditions to be satisfied (or waived), including insufficient shares of Sage common stock being tendered in the tender offer; the failure (or delay) to receive the required regulatory approvals of the proposed acquisition; the possibility that prior to the completion of the transactions contemplated by the acquisition agreement, Supernus' or the Sage's business may experience significant disruptions due to transaction related uncertainty; the effects of disruption from the transactions of Sage's business and the fact that the announcement and pendency of the transactions may make it more difficult to establish or maintain relationships with employees, manufactures, suppliers, vendors, business partners and distribution channels to patients; the occurrence of any event, change or other circumstance that could give rise to the termination of the acquisition agreement; the risk that stockholder litigation in connection with the proposed transaction may result in significant costs of defense, indemnification and liability; the failure of the closing conditions set forth in the acquisition agreement to be satisfied or waived; Supernus' ability to sustain and increase its profitability; Supernus' ability to raise sufficient capital to fully implement its corporate strategy; the implementation of Supernus' corporate strategy; Supernus' future financial performance and projected expenditures; Supernus' ability to increase the number of prescriptions written for each of its products and products acquired through the acquisition of Sage; Supernus' ability to increase its net revenue from its products and products acquired through the acquisition of Sage; Supernus' ability to commercialize its products including Qelbree; Supernus' ability to enter into future collaborations with pharmaceutical companies and academic institutions or to obtain funding from government agencies; Supernus' product research and development activities, including the timing and progress of Supernus' clinical trials, and projected expenditures; Supernus' ability to receive, and the timing of any receipt of, regulatory approvals to develop and commercialize Supernus' product candidates; Supernus' ability to protect its intellectual property and operate its business without infringing upon the intellectual property rights of others; Supernus' expectations regarding federal, state and foreign regulatory requirements; the therapeutic benefits, effectiveness and safety of Supernus' product candidates; the accuracy of Supernus' estimates of the size and characteristics of the markets that may be addressed by its product candidates; Supernus' ability to increase its manufacturing capabilities for its products and product candidates; Supernus' projected markets and growth in markets; Supernus' product formulations and patient needs and potential funding sources; Supernus' staffing needs; and other risk factors set forth from time to time in Supernus' filings with the Securities and Exchange Commission made pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended. Supernus undertakes no obligation to update the information in this press release to reflect events or circumstances after the date hereof or to reflect the occurrence of anticipated or unanticipated events. Sage Forward Looking Statements This press release contains forward-looking statements related to Sage, Supernus, the tender offer for outstanding shares of Sage common stock (the 'Offer'), the merger of Saphire, Inc., a Delaware corporation and a wholly owned subsidiary of Supernus with and into Sage, with Sage surviving as a wholly owned subsidiary of Supernus (the 'Merger'), the Agreement and Plan of Merger, dated June 13, 2025, by and among Supernus, Purchaser, and Sage (the 'Merger Agreement') and the other transactions contemplated by the Merger Agreement (collectively, the 'Transactions') that involve substantial risks and uncertainties. Forward-looking statements include any statements containing the words 'anticipate,' 'believe,' 'contemplate,' 'estimate,' 'expect,' 'intend', 'goal,' 'may', 'might,' 'plan,' 'predict,' 'project,' 'seek,' 'opportunity,' 'target,' 'potential,' 'will,' 'would,' 'could,' 'should,' 'continue' and similar expressions. In this press release, Sage's forward-looking statements include statements about the parties' ability to satisfy the conditions to the consummation of the Offer and the other conditions to the consummation of the Transactions; statements about the expected timetable for completing the Transactions; Sage's plans, objectives, expectations and intentions; the financial condition, results of operations and business of Sage and Supernus; Sage's ability to commercialize current and future product candidates (including further commercialization of ZURZUVAE); and the anticipated timing of the closing of the Transactions. Forward-looking statements are subject to certain risks, uncertainties or other factors that are difficult to predict, and could cause actual events or results to differ materially from those indicated in any such statements due to a number of risks and uncertainties. Those risks and uncertainties that could cause the actual results to differ from expectations contemplated by forward-looking statements include, among other things: uncertainties as to the timing of the Offer and the Merger; uncertainties as to how many of Sage's stockholders will tender their Shares in the Offer; risks related to non-achievement of the CVR milestones and that holders of the CVRs will not receive any payments in respect of those CVRs; the possibility that competing offers will be made; the possibility that various closing conditions for the Transactions may not be satisfied or waived, including that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the Transactions; the effects of the Transactions on relationships with employees, other business partners or governmental entities; the difficulty of predicting the timing or outcome of U.S. Food and Drug Administration approvals or actions, if any; the impact of competitive products and pricing; that Supernus may not realize the potential benefits of the Transactions; other business effects, including the effects of industry, economic or political conditions outside of the companies' control; transaction costs; actual or contingent liabilities; Sage's launch and commercialization efforts in the U.S. with respect to ZURZUVAE for the treatment of women with PPD may not be successful; ZURZUVAE may not achieve the clinical benefit, clinical use or market acceptance for the treatment of PPD Sage or Supernus expects or they may encounter reimbursement, market access, process-related or other issues, including competition in the market, that impact the success of their commercialization efforts; ZURZUVAE may never become the standard of care for women with PPD; and other risks listed under the heading 'Risk Factors' in the Company's periodic reports filed with the U.S. Securities and Exchange Commission, including current reports on Form 8-K, quarterly reports on Form 10-Q, annual reports on Form 10-K, as well as the Schedule 14D-9 to be filed by Sage and the Schedule TO and related tender offer documents to be filed by Supernus and Purchaser. You should not place undue reliance on these statements. All forward-looking statements are based on information currently available to Sage and Supernus, and Sage and Supernus disclaim any obligation to update the information contained in this press release as new information becomes available. SELECT IMPORTANT SAFETY INFORMATION FOR ZURZUVAE ZURZUVAE (zuranolone) CIV, is a neuroactive steroid gamma-aminobutyric acid (GABA) A receptor positive modulator indicated for the treatment of postpartum depression in adults. This does not include all the information needed to use ZURZUVAE safely and effectively. See full prescribing information for ZURZUVAE. ZURZUVAE may cause serious side effects, including decreased awareness and alertness, which can affect your ability to drive safely or safely do other dangerous activities. Do not drive, operate machinery, or do other dangerous activities until at least 12 hours after taking each dose. You may not be able to tell on your own if you can drive safely or tell how much ZURZUVAE is affecting you. ZURZUVAE may cause central nervous system (CNS) depressant effects including sleepiness, drowsiness, slow thinking, dizziness, confusion, and trouble walking. Taking alcohol, other medicines that cause CNS depressant effects such as benzodiazepines, or opioids while taking ZURZUVAE can make these symptoms worse and may also cause trouble breathing. ZURZUVAE is a federally controlled substance schedule IV because it contains zuranolone, which can be abused or lead to dependence. Tell your healthcare provider right away if you become pregnant or plan to become pregnant during treatment with ZURZUVAE. You should use effective birth control (contraception) during treatment with ZURZUVAE and for 1 week after the final dose. ZURZUVAE and other antidepressant medicines may increase the risk of suicidal thoughts and actions in people 24 years of age and younger. ZURZUVAE is not for use in children. The most common side effects of ZURZUVAE include sleepiness or drowsiness, dizziness, common cold, diarrhea, feeling tired, weak, or having no energy, and urinary tract infection. Supernus Pharmaceuticals ContactsJack A. Khattar, President and CEOTim Dec, Senior Vice President and CFOSupernus Pharmaceuticals, Inc.(301) 838-2591 Investors:Peter VozzoICR Healthcare(443) 213-0505Email: Sage Therapeutics ContactsInvestor ContactAshley Media ContactFrancesca in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
